Pancuronium bromide induced joint contractures in the newborn

Area of Science:

• Neonatal care
• Pediatric pharmacology
• Neuromuscular blockade

Background:

• Mechanical ventilation is a critical support for critically ill infants.
• Pancuronium bromide is a neuromuscular blocking agent used to facilitate mechanical ventilation.
• Understanding potential adverse effects of medications in neonates is crucial.

Observation:

• Three infants receiving pancuronium bromide for mechanical ventilation developed multiple joint contractures.
• Two term infants also received gentamicin and phenobarbitone concurrently.
• One preterm infant had pre-existing contractures that worsened post-paralysis.

Findings:

• Pancuronium bromide administration in infants may be associated with the development of joint contractures.
• Concomitant use of gentamicin and phenobarbitone might potentiate pancuronium bromide's effects, increasing contracture risk.
• Pre-existing joint contractures can be exacerbated by pancuronium bromide therapy.

Implications:

• Clinicians should be vigilant for joint contractures in infants treated with pancuronium bromide.
• Potential drug interactions with pancuronium bromide in neonates require careful consideration.
• Further research is needed to elucidate the mechanisms and risk factors for pancuronium-induced contractures.